Eli Lilly and Company (NYSE:LLY) Position Cut by Lifestyle Asset Management Inc.

Lifestyle Asset Management Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.2% in the 1st quarter, Holdings Channel reports. The fund owned 388 shares of the company’s stock after selling 54 shares during the period. Lifestyle Asset Management Inc.’s holdings in Eli Lilly and Company were worth $302,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc raised its stake in shares of Eli Lilly and Company by 1.8% during the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after purchasing an additional 13 shares in the last quarter. Moseley Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 0.4% in the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the period. CGN Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after acquiring an additional 14 shares in the last quarter. Buckhead Capital Management LLC increased its stake in shares of Eli Lilly and Company by 0.7% during the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after acquiring an additional 15 shares during the period. Finally, Levin Capital Strategies L.P. raised its holdings in Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 858,742 shares of company stock worth $735,573,781. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.9 %

NYSE:LLY traded down $8.61 on Wednesday, hitting $898.10. 3,076,361 shares of the company’s stock traded hands, compared to its average volume of 2,948,155. The company has a market cap of $853.56 billion, a PE ratio of 132.27, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $918.50. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a 50-day moving average price of $821.29 and a 200-day moving average price of $745.62.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the firm posted $1.62 earnings per share. The firm’s revenue was up 26.0% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analyst Ratings Changes

A number of equities analysts have issued reports on LLY shares. Citigroup increased their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday. Bank of America reissued a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.